Overview
- The FDA’s Pharmacy Compounding Advisory Committee will meet on Thursday and Friday to advise whether BPC‑157, TB‑500, Semax, Epitalon, Emideltide, KPV, and MOTS‑c should be added to the agency’s 503A Bulks List for prescription compounding.
- Agency scientists have recommended against reclassifying the seven peptides because there are few human clinical trials and limited pharmacology and toxicology data to show safety or effective dosing.
- Consumer demand for these peptides is high and a May survey found 83% of peptide‑aware Americans support expanded prescription access, a trend that has fueled an online gray market selling unregulated, research‑grade injections.
- Industry players and telehealth clinics are preparing to scale peptide prescribing if the panel recommends recategorization, but any committee approval would be advisory and not equivalent to formal FDA drug approval.
- Experts warn of specific risks from the current unregulated supply and from the molecules themselves, including wrong dosing, contaminants, impurities, possible immune reactions, and unknown long‑term effects, and some reports note advisory‑committee ties to peptide businesses that raise conflict concerns.